Results 61 to 70 of about 81,769 (261)

Glioblastoma Stem Cells as a New Therapeutic Target for Glioblastoma

, 2015
Primary and secondary glioblastomas (GBMs) are two distinct diseases. The genetic and epigenetic background of these tumors is highly variable. The treatment procedure for these tumors is often unsuccessful because of the cellular heterogeneity and ...
Rasime Kalkan
core   +1 more source

Expanding the Hippo pathway : hMOB3 modulates apoptotic MST1 signaling and supports tumor growth in glioblastoma [PDF]

, 2014
Protein kinases are critical players of signal transduction pathways involved in development, physiological and pathological processes. Deregulation of protein kinase signaling is found to be causal or related to varieties of human diseases, such as ...
Tang, Fengyuan
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Modulation of the blood–brain barrier permeability by patient-derived glioblastoma stem cell secretome

Scientific Reports
The blood–brain barrier (BBB) is a highly selective barrier that strictly controls the passage of substances and cells into the brain, protecting it from potential harm while preserving homeostasis.
Francesco Saverio Sica, Michela Patrucco, Martina Giambra, Martina Ghizzi, Silvia Sesana, Barbara Vergani, Biagio Eugenio Leone, Andrea Di Cristofori, Carlo Giorgio Giussani, Gabriella Nicolini, Angela Bentivegna, Francesca Re   +11 more
doaj   +1 more source

Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status

Pharmaceuticals, 2021
Glioblastoma is a malignant brain tumor and one of the most lethal cancers in human. Temozolomide constitutes the standard chemotherapeutic agent, but only shows limited efficacy in glioblastoma patients with unmethylated O-6-methylguanine-DNA ...
Matthias Schneider, Anna-Laura Potthoff, Bernd O. Evert, Marius Dicks, Denise Ehrentraut, Andreas Dolf, Elena N. C. Schmidt, Niklas Schäfer, Valeri Borger, Torsten Pietsch, Mike-Andrew Westhoff, Erdem Güresir, Andreas Waha, Hartmut Vatter, Dieter H. Heiland, Patrick Schuss, Ulrich Herrlinger   +16 more
doaj   +1 more source

The translatome of glioblastoma

Molecular Oncology
Glioblastoma (GB), the most common and aggressive brain tumor, demonstrates intrinsic resistance to current therapies, resulting in poor clinical outcomes. Cancer progression can be partially attributed to the deregulation of protein translation mechanisms that drive cancer cell growth.
Fleur M. G. Cornelissen, Zhaoren He, Edward Ciputra, Richard R. de Haas, Ammarina Beumer‐Chuwonpad, David Noske, W. Peter Vandertop, Sander R. Piersma, Connie R. Jiménez, Cornelis Murre, Bart A. Westerman   +10 more
openaire   +3 more sources

Fermented mistletoe extract as a multimodal antitumoral agent in gliomas [PDF]

, 2012
In Europe, commercially available extracts from the white-berry mistletoe (Viscum album L.) are widely used as a complementary cancer therapy. Mistletoe lectins have been identified as main active components and exhibit cytotoxic effects as well as ...
Mittelbronn, Michel Guy André, Michel Mittelbronn, Harter, Patrick Nikolaus, Oliver Podlech, Pöschel, Simone, Ulrike Naumann, Naumann, Ulrike, Podlech, Oliver, Patrick N. Harter   +8 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Identifying the role of Mer receptor tyrosine kinase in glioblastoma multiforme [PDF]

, 2012
GBM is one of the most aggressive human cancers. Primary GBM, which comprises more than 90% of biopsied or resected brain tumors, arises de novo without an antecedent history of low-grade disease.
Yuhua, Wang
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source